Epigenetic mechanisms of pulmonary hypertension

Pulmonary Circulation

Volumn 1, Issue 3, 2011, Pages 347-356

  Kim, Gene H ^a   Ryan, John J ^a   Marsboom, Glenn ^a   Archer, Stephen L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

CpG islands; DNA methyl transferases; Histone acetylation; Small inhibitor RNA; Superoxide dismutase 2

Indexed keywords

EID: 84866028172     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.87300     Document Type: Review

References (76)

1. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, et al. Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: A basis for excessive cell proliferation and a new therapeutic target. Circulation 2010;121:2661-71.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-4.
3. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Human Genet 2000;67:737-44.
4. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, et al. Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 2008;1:45.
5. Nagaoka T, Muramatsu M, Sato K, McMurtry I, Oka M, Fukuchi Y. Mild hypoxia causes severe pulmonary hypertension in fawn-hooded but not in Tester Moriyama rats. Respir Physiol 2001;127:53-60.
6. Wideman RF Jr, Hamal KR. Idiopathic pulmonary arterial hypertension: An avian model for plexogenic arteriopathy and serotonergic vasoconstriction. J Pharm Toxicol Methods 2011;63:283-95.
7. Julian RJ. Physiological, management and environmental triggers of the ascites syndrome: A review. Avian Pathol 2000;29:519-27.
8. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009;69:9073-82.
9. Esteller M, Fraga MF, Paz MF, Campo E, Colomer D, Novo FJ, et al. Cancer epigenetics and methylation. Science 2002;297:1807-8; discussion 1807-8.
10. Ho SM. Environmental epigenetics of asthma: An update. J Allergy Clin Immunol 2010;126:453-65.
11. Beaudet AL. Allan Award lecture: Rare patients leading to epigenetics and back to genetics. Am J Hum Genet 2008;82:1034-8.
12. Grafodatskaya D, Chung B, Szatmari P, Weksberg R. Autism spectrum disorders and epigenetics. J Am Acad Child Adolesc Psychiatry 2010;49:794-809.
13. Lalande M, Calciano MA. Molecular epigenetics of Angelman syndrome. Cell Mol Life Sci 2007;64:947-60.
14. Glenn CC, Deng G, Michaelis RC, Tarleton J, Phelan MC, Surh L, et al. DNA methylation analysis with respect to prenatal diagnosis of the Angelman and Prader-Willi syndromes and imprinting. Prenat Diagn 2000;20:300-6.
15. Holliday R. Epigenetics: An overview. Dev Genet 1994;15:453-7.
16. Sawan C, Vaissière T, Murr R, Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutat Res 2008;642:1-13.
17. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
18. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000;16:168-74.
19. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009;1:239-59.
20. Wild L, Flanagan JM. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 2010;1806:50-7.
21. De Smet C, Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics official journal of the DNA Methylation Society 2010;5:206-13.
22. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. International journal of cancer. Int J Cancer 2009;124:81-7.
23. Guerrero-Preston R, Santella RM, Blanco A, Desai M, Berdasco M, Fraga M. Global DNA hypomethylation in liver cancer cases and controls: A phase I preclinical biomarker development study. Epigenetics: official journal of the DNA Methylation Society 2007;2:223-6.
24. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 2007;447:425-32.
25. Illingworth R, Bird A. CpG islands: “a rough guide.” FEBS Lett 2009;583:1713-20.
26. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001;293:1068-70.
27. Aoyama T, Okamoto T, Nagayama S, Nishijo K, Ishibe T, Yasura K, et al. Methylation in the corepromoter region of the chondromodulin-I gene determines the cell specific expression by regulating the binding of transcriptional activator Sp3. J Biol Chem 2004;279:28789-97.
28. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: Basic mechanisms and role in cardiovascular disease. Circulation 2011;123:2145-56.
29. Griffiths E, Gore S. MicroRNA: mIR-ly regulators of DNMT? Blood 2009;113:6269-70.
30. Svedružić Ž. Dnmt1 structure and function. Prog Mol Biol Transl Sci 2011;101:221-54.
31. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:247-57.
32. Jenuwein T, Allis C. Translating the histone code. Science 2001;293:1074-80.
33. Bartel D. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
34. Huang Y, Zou Q, Song H, Song F, Wang L, Zhang G, et al. A study of miRNAs targets prediction and experimental validation. Protein Cell 2010;1:979-86.
35. John B, Sander C, Marks D. Prediction of human microRNA targets. Methods Mol Biol 2006;342:101-13.
36. Agirre X, Vilas-Zornoza A, Jiménez-Velasco A, Martin-Subero JI, Cordeu L, Gárate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009;69:4443-53.
37. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-23.
38. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-10.
39. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010;31:766-76.
40. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-29.
41. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61:24R-9R.
42. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 2009;113:6411-8.
43. Bravard A, Sabatier L, Hoffschir F, Ricoul M, Luccioni C, Dutrillaux B. SOD2: A new type of tumor-suppressor gene? Int J Cancer 1992;51:476-80.
44. Hitchler M, Oberley L, Domann F. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. Free Radic Biol Med 2008;45:1573-80.
45. Hurt E, Thomas SB, Peng B, Farrar WL. Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines. Br J Cancer 2007;97:1116-23.
46. Hitchler MJ, Oberley LW, Domann FE. Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells. Free Radic Biol Med 2008;45:1573-80.
47. Hitchler MJ, Wikainapakul K, Yu L, Powers K, Attatippaholkun W, Domann FE. Epigenetic regulation of manganese superoxide dismutase expression in human breast cancer cells. Epigenetics 2006;1:163-71.
48. Huang L, Arany Z, Livingston DM, Bunn HF. Activation of hypoxiainducible transcription factor depends primarily upon redoxsensitive stabilization of its alpha subunit. J Biol Chem 1996;271:32253-9.
49. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004;169:764-9.
50. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113: 2630-41.
51. Farha S, Asosingh K, Xu W, Sharp J, George D, Comhair S, et al. Hypoxiainducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities. Blood 2011;117:3485-93.
52. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, Krishnamachary B, et al. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 2010;176:1130-8.
53. Barker DJ, Osmond C, Simmonds SJ, Wield GA. The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life. BMJ 1993;306:422-6.
54. Painter RC, Roseboom TJ, Bleker OP. Prenatal exposure to the Dutch famine and disease in later life: an overview. Reprod Toxicol 2005;20:345-52.
55. Rexhaj E, Bloch J, Jayet PY, Rimoldi SF, Dessen P, Mathieu C, et al. Fetal programming of pulmonary vascular dysfunction in mice: role of epigenetic mechanisms. Am J Physiol Heart Circ Physiol 2011;301:H247-52.
56. Therese P. Persistent pulmonary hypertension of the newborn. Paediatr Respir Rev 2006;7:S175-6.
57. Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 2007;120:e272-82.
58. Hoehn T, Preston AA, McPhaden AR, Stiller B, Vogel M, Bührer C, et al. Endothelial nitric oxide synthase (NOS) is upregulated in rapid progressive pulmonary hypertension of the newborn. Intensive Care Med 2003;29:1757-62.
59. Xu XF, Ma XL, Shen Z, Wu XL, Cheng F, Du LZ. Epigenetic regulation of the endothelial nitric oxide synthase gene in persistent pulmonary hypertension of the newborn rat. J Hypertens 2010;28:2227-35.
60. Fish J, Marsden P. Endothelial nitric oxide synthase: insight into cellspecific gene regulation in the vascular endothelium. Cell Mol Life Sci 2006;63:144-62.
61. Chan Y, Fish JE, D’Abreo C, Lin S, Robb GB, Teichert AM, et al. The cellspecific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem 2004;279:35087-100.
62. Gan Y, Shen YH, Wang J, Wang X, Utama B, Wang J, et al. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem 2005;280:16467-75.
63. Piao L, Marsboom G, Archer SL. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) 2010;88:1011-20.
64. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010;138:1234-9.
65. Cho YK, Eom GH, Kee HJ, Kim HS, Choi WY, Nam KI, et al. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 2010;74:760-70.
66. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, et al. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 2011;183:1402-10.
67. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006;113:2579-88.
68. Kreymborg K, Uchida S, Gellert P, Schneider A, Boettger T, Voswinckel R, et al. Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. J Mol Cell Cardiol 2010;49:598-605.
69. Herceg Z, Ushijima T. Introduction: Epigenetics and cancer. Adv Genet 2010;70:1-23.
70. Eberl HC, Mann M. Vermeulen M. Quantitative proteomics for epigenetics. Chembiochem 2011;12:224-34.
71. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007;22:91-103.
72. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK, et al. SMRTmediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007;450:415-9.
73. Huang YW, Kuo CT, Stoner K, Huang TH, Wang LS. An overview of epigenetics and chemoprevention. FEBS Lett 2011;585:2129-36.
74. Pray-Grant M, Daniel JA, Schieltz D, Yates JR 3rd, Grant PA. Chd1 chromodomain links histone H3 methylation with SAGA-and SLIKdependent acetylation. Nature 2005;433:434-8.
75. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002;298:1039-43.
76. Bártová E, Krejcí J, Harnicarová A, Galiová G, Kozubek S. Histone modifications and nuclear architecture: a review. J Histochem Cytochem 2008;56:711-21.